Physiologically based mechanistic modelling to predict complex drug–drug interactions involving simultaneous competitive and time-dependent enzyme inhibition by parent compound and its metabolite in both liver and gut—The effect of diltiazem on the time-course of exposure to triazolam-Reference-Cited by-同舟云学术

Physiologically based mechanistic modelling to predict complex drug–drug interactions involving simultaneous competitive and time-dependent enzyme inhibition by parent compound and its metabolite in both liver and gut—The effect of diltiazem on the time-course of exposure to triazolam

Published:2010-03 Issue:5 Volume:39 Page:298-309
ISSN:0928-0987
Container-title:European Journal of Pharmaceutical Sciences
language:en
Short-container-title:European Journal of Pharmaceutical Sciences

Author:

Rowland Yeo Karen,Jamei Masoud,Yang Jiansong,Tucker Geoffrey T.,Rostami-Hodjegan Amin

Publisher

Elsevier BV

Subject

Pharmaceutical Science

Reference65 articles.

1. The influence of nonspecific microsomal binding on apparent intrinsic clearance, and its prediction from physicochemical properties;Austin;Drug Metab. Dispos.,2002

2. Dose of midazolam should be reduced during diltiazem and verapamil treatments;Backman;Br. J. Clin. Pharmacol.,1994

3. Coadministration of nefazodone and benzodiazepines. II. A pharmacokinetic interaction study with triazolam;Barbhaiya;J. Clin. Psychopharmacol.,1995

4. Covariation of human microsomal protein per gram of liver with age: absence of influence of operator and sample storage may justify interlaboratory data pooling;Barter;Drug Metab. Dispos.,2008

5. The pharmacokinetics and pharmacodynamics of diltiazem and its metabolites in healthy adults after a single oral dose;Boyd;Clin. Pharmacol. Ther.,1989

Cited by 166 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advancements in physiologically based pharmacokinetic modeling for fedratinib: updating dose guidance in the presence of a dual inhibitor of CYP3A4 and CYP2C19;Cancer Chemotherapy and Pharmacology;2024-08-07

2. Physiologically‐based pharmacokinetic modeling of the drug–drug interaction between ivacaftor and lefamulin in cystic fibrosis patients;CPT: Pharmacometrics & Systems Pharmacology;2024-02

3. Evaluation of the potential impact on pharmacokinetics of various cytochrome P450 substrates of increasing IL‐6 levels following administration of the T‐cell bispecific engager glofitamab;CPT: Pharmacometrics & Systems Pharmacology;2023-12-14

4. Prediction of CYP Down Regulation after Tusamitamab Ravtansine Administration (a DM4‐Conjugate), Based on an In Vitro–In Vivo Extrapolation Approach;Clinical Pharmacology & Therapeutics;2023-12-03

5. Assessing Dose-Exposure–Response Relationships of Miltefosine in Adults and Children using Physiologically-Based Pharmacokinetic Modeling Approach;Pharmaceutical Research;2023-10-10